Skip to main content

Medical and radiation oncology

Section edited by Dirk Vordermark

This section focuses on clinical research that impacts on the treatment of cancer using systemic chemotherapy, targeted therapy, and radiation.

Page 5 of 20

  1. The relationship between lung dose-volume histogram (DVH) parameters and radiation pneumonitis (RP) associated with induction concurrent chemoradiotherapy (CCRT) followed by surgery in patients with non-small ...

    Authors: Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Norihisa Katayama, Junichi Soh, Masahiro Kuroda, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka and Susumu Kanazawa

    Citation: BMC Cancer 2019 19:1144

    Content type: Research article

    Published on:

  2. Chemotherapy can improve the survival of patients with advanced gastric cancer. However, whether triplet chemotherapy can further improve the survival of patients with advanced gastric cancer compared with dou...

    Authors: Xinjian Guo, Fuxing Zhao, Xinfu Ma, Guoshuang Shen, Dengfeng Ren, Fangchao Zheng, Feng Du, Ziyi Wang, Raees Ahmad, Xinyue Yuan, Junhui Zhao and Jiuda Zhao

    Citation: BMC Cancer 2019 19:1125

    Content type: Research article

    Published on:

  3. To assess the efficacy of Nimotuzumab in combination with first-line chemoradiotherapy treatment in Chinese patients with primary III-IVb stage nasopharyngeal carcinoma.

    Authors: Wang Zhi-Qiang, Mei Qi, Li Ji-Bin, You Rui, Liu You-Ping, Sun Rui, Hu Guang-Yuan, Chen Ming-Yuan and Hua Yi-Jun

    Citation: BMC Cancer 2019 19:1122

    Content type: Research article

    Published on:

  4. Chemotherapy-induced nausea and vomiting (CINV) belong among the most burdensome side effects in hemato-oncology. Mostly, a combination of ondansetron and dexamethasone is used as antiemetic prophylaxis in ped...

    Authors: Semjon Willier, Karin Melanie Cabanillas Stanchi, Martina von Have, Vera Binder, Franziska Blaeschke, Judith Feucht, Tobias Feuchtinger and Michaela Döring

    Citation: BMC Cancer 2019 19:1118

    Content type: Research article

    Published on:

  5. The majority of patients with head and neck squamous cell carcinoma (HNSCC) receive bilateral elective nodal irradiation (ENI), in order to reduce the risk of regional failure. Bilateral ENI, as compared to un...

    Authors: Pieter D. de Veij Mestdagh, Willem H. Schreuder, Wouter V. Vogel, Maarten L. Donswijk, Eric van Werkhoven, Jacqueline E. van der Wal, Richard Dirven, Baris Karakullukcu, Jan-Jakob Sonke, Michiel W. M. van den Brekel, Corrie A. M. Marijnen and Abrahim Al-Mamgani

    Citation: BMC Cancer 2019 19:1110

    Content type: Study protocol

    Published on:

  6. To explore the patterns of failures and areas at highest risk of recurrence for postoperative intrahepatic cholangiocarcinoma (IHCC), with the aim to guide IHCC adjuvant radiotherapy.

    Authors: Wei Yu, Chunxiu Hu, Yongjie Shui, Kui Wu, Lili Zhang, Ying Chen, Chao Li, Jing Xu and Qichun Wei

    Citation: BMC Cancer 2019 19:1108

    Content type: Research article

    Published on:

  7. The relationship between whole brain radiotherapy (WBRT) dose with intracranial tumor control and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) brain metastases (BM) is largely unkn...

    Authors: Zhensheng Li, Dongxing Shen, Jian Zhang, Jun Zhang, Fang Yang, Deyou Kong, Jie Kong and Andu Zhang

    Citation: BMC Cancer 2019 19:1104

    Content type: Research article

    Published on:

  8. The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in th...

    Authors: Hannah L. Buckley, Fiona J. Collinson, Gemma Ainsworth, Heather Poad, Louise Flanagan, Eszter Katona, Helen C. Howard, Geraldine Murden, Rosamonde E. Banks, Joanne Brown, Galina Velikova, Tom Waddell, Kate Fife, Paul D. Nathan, James Larkin, Thomas Powles…

    Citation: BMC Cancer 2019 19:1102

    Content type: Study protocol

    Published on:

  10. The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic targe...

    Authors: Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Jung Yong Hong, Ho Sup Lee, Sung Yong Oh, Ho-Jin Shin, Jee Hyun Kong, Jun Ho Yi, Kana Sakamoto, Young Hyeh Ko, Jooryung Huh, Seung-Sook Lee, Kengo Takeuchi, Dong-Yeop Shin, Cheolwon Suh…

    Citation: BMC Cancer 2019 19:1080

    Content type: Research article

    Published on:

  11. Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free su...

    Authors: Farastuk Bozorgmehr, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Jonas Kuon, Martin Maenz, Peter E. Huber, Laila König, Meinhard Kieser, Juergen Debus, Michael Thomas and Stefan Rieken

    Citation: BMC Cancer 2019 19:1074

    Content type: Study protocol

    Published on:

  13. Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the qu...

    Authors: Jing Zhang, Yunyun Wang, Hong Weng, Danqi Wang, Fei Han, Qiao Huang, Tong Deng, Xinghuan Wang and Yinghui Jin

    Citation: BMC Cancer 2019 19:1054

    Content type: Research article

    Published on:

  14. Local consolidative treatment (LCT) is important for oligometastasis, defined as the restricted metastatic capacity of a tumor. This study aimed to determine the effects and prognostic heterogeneity of LCT in ...

    Authors: Jia-Tao Zhang, Si-Yang Liu, Hong-Hong Yan, Yi-Long Wu, Qiang Nie and Wen-Zhao Zhong

    Citation: BMC Cancer 2019 19:1051

    Content type: Research article

    Published on:

  15. Budding is a complementary prognostic factor for colorectal cancer. In this study, we aimed to clarify the role of tumor budding in rectal cancer patients after preoperative chemoradiotherapy.

    Authors: Iryna Trotsyuk, Halina Sparschuh, Alice Josephine Müller, Konrad Neumann, Martin Kruschewski, David Horst and Sefer Elezkurtaj

    Citation: BMC Cancer 2019 19:1033

    Content type: Research article

    Published on:

  16. Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MT...

    Authors: John H. Strickler, Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, Michael A. Morse, David Z. Chang, James L. Wells, Kimberly L. Blackwell, P. Kelly Marcom, Christy Arrowood, Emily Bolch, Sherri Haley…

    Citation: BMC Cancer 2019 19:1032

    Content type: Research article

    Published on:

  17. Infusion of high-dose intravenous methotrexate (MTX) has been demonstrating to penetrate the blood-brain barrier. The aim of this present study was to assess the efficacy and safety of high dose MTX in patient...

    Authors: F. Bazan, E. Dobi, B. Royer, E. Curtit, L. Mansi, N. Menneveau, M. J. Paillard, G. Meynard, C. Villanueva, X. Pivot and L. Chaigneau

    Citation: BMC Cancer 2019 19:1029

    Content type: Research article

    Published on:

  18. The aim of the present study was to assess the efficacy of postoperative chemoradiotherapy (POCRT) following surgery in non-small-cell lung cancer patients with N2 lymph node metastasis (N2-NSCLC).

    Authors: Liyu Su, Mingqiu Chen, Huiyan Su, Yaqing Dai, Shaoxing Chen and Jiancheng Li

    Citation: BMC Cancer 2019 19:1023

    Content type: Research article

    Published on:

  19. Nivolumab is an immune checkpoint inhibitor specific to the programmed death 1 (PD-1) receptor. Nivolumab has shown clinical responses in many malignancies. Although immune-related adverse events (irAEs) assoc...

    Authors: Koji Yoshino, Takayuki Nakayama, Ayumu Ito, Eiichi Sato and Shigehisa Kitano

    Citation: BMC Cancer 2019 19:1019

    Content type: Case report

    Published on:

  20. Bone metastases in the lower spine and pelvis are effectively palliated with radiotherapy (RT), though this can come with side effects such as radiation induced nausea and vomiting (RINV). We hypothesize that ...

    Authors: Robert Olson, Roel Schlijper, Nick Chng, Quinn Matthews, Marco Arimare, Lindsay Mathews, Fred Hsu, Tanya Berrang, Alexander Louie, Benjamin Mou, Boris Valev, Joanna Laba, David Palma, Devin Schellenberg and Shilo Lefresne

    Citation: BMC Cancer 2019 19:1011

    Content type: Study protocol

    Published on:

  21. Non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations often develop brain metastases. Treatment with EGFR-tyrosine kinase inhibitors (TKIs) has shown the effec...

    Authors: Yung-Hsuan Chen, Yen-Fu Chen, Chung-Yu Chen, Jin-Yuan Shih and Chong-Jen Yu

    Citation: BMC Cancer 2019 19:1006

    Content type: Research article

    Published on:

  22. The survival rate of patients with advanced oesophageal cancer is very low and can vary significantly, even among patients with the same TNM stage. It is important to look for indicators that are economical an...

    Authors: Ke-Jie Li, Xiao-Fang Xia, Meng Su, Hui Zhang, Wen-Hao Chen and Chang-Lin Zou

    Citation: BMC Cancer 2019 19:1004

    Content type: Research article

    Published on:

  23. Leptomeningeal metastasis (LM) is a predominantly late stage, devastating complication of a variety of malignant solid tumors. Diagnosis relies predominantly on neurological, radiographic, and cerebrospinal fl...

    Authors: Ann-Kathrin Stoppek, Sied Kebir, Andreas Junker, Kathy Keyvani, Stefan Zülow, Lazaros Lazaridis, Teresa Schmidt, Daniela Pierscianek, Martin Stuschke, Ulrich Sure, Christoph Kleinschnitz, Björn Scheffler, Lisa Zimmer and Martin Glas

    Citation: BMC Cancer 2019 19:995

    Content type: Case report

    Published on:

  24. Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of advanced cases at the time of diagnosis. Advanced BTCs ...

    Authors: L. Perkhofer, A. W. Berger, A. K. Beutel, E. Gallmeier, S. Angermeier, L. Fischer von Weikersthal, T. O. Goetze, R. Muche, T. Seufferlein and T. J. Ettrich

    Citation: BMC Cancer 2019 19:990

    Content type: Study protocol

    Published on:

  25. While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF). While AFF has been reported in patients...

    Authors: Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi and Toshimi Takano

    Citation: BMC Cancer 2019 19:980

    Content type: Research article

    Published on:

  26. Conventionally fractionated (CF) radiation therapy (RT) has been associated with lymphopenia, leading to compromised overall survival (OS) in cancer patients. It currently remains unknown if stereotactic body ...

    Authors: Guangyin Wu, Michael J. Baine, Nan Zhao, Sicong Li, Xiaobo Li and Chi Lin

    Citation: BMC Cancer 2019 19:977

    Content type: Research article

    Published on:

  27. Patients with metastatic renal carcinoma frequently have pre-existing renal impairment and not infrequently develop worsening renal function as a complication of their treatment. The presence of pancreatic met...

    Authors: Karin Purshouse, Sarah Chamberlain, Maria Soares, Mark Tuthill, Andrew Protheroe and David R. Mole

    Citation: BMC Cancer 2019 19:967

    Content type: Case report

    Published on:

  28. Sarcomatoid carcinoma of unknown primary (SCUP) is a rare entity of either poorly differentiated carcinoma with sarcoma-like differentiation or a true mixed lineage neoplasm. Limited data regarding clinicopath...

    Authors: Ryan W. Huey, Shalini Makawita, Lianchun Xiao, Aurelio Matamoros, Jeannelyn S. Estrella, Michael J. Overman, Gauri R. Varadhachary and Kanwal Raghav

    Citation: BMC Cancer 2019 19:965

    Content type: Research article

    Published on:

  29. Neuroblastoma is the most common extra-cranial solid tumor among children. Despite intensive treatment, patients with advanced disease mostly experience dismal outcomes. Here, we proposed the use of topotecan ...

    Authors: Piya Rujkijyanont, Apichat Photia, Chanchai Traivaree, Chalinee Monsereenusorn, Usanarat Anurathapan, Panya Seksarn, Darintr Sosothikul, Piti Techavichit, Kleebsabai Sanpakit, Kamon Phuakpet, Surapon Wiangnon, Thirachit Chotsampancharoen, Su-on Chainansamit, Somjai Kanjanapongkul, Arunotai Meekaewkunchorn and Suradej Hongeng

    Citation: BMC Cancer 2019 19:961

    Content type: Research article

    Published on:

  30. Neuroendocrine tumors (NETs) are heterogeneous, widely distributed tumors arising from neuroendocrine cells. Gastrointestinal (GI)-NETs are the most common and NETs of the rectum represent 15, 2% of gastrointe...

    Authors: Gemma Bruera, Antonio Giuliani, Lucia Romano, Alessandro Chiominto, Alessandra Di Sibio, Stefania Mastropietro, Pierluigi Cosenza, Enrico Ricevuto, Mario Schietroma and Francesco Carlei

    Citation: BMC Cancer 2019 19:960

    Content type: Case report

    Published on:

  31. Paclitaxel is used in second-line conventional chemotherapies to manage patients with unresectable advanced gastric cancer (GC). Paclitaxel-induced peripheral neuropathy is a known adverse event leading to tre...

    Authors: Hiroaki Tanioka, Takeshi Nagasaka, Futoshi Uno, Masafumi Inoue, Hiroyuki Okita, Yosuke Katata, Hiromitsu Kanzaki, Hidekazu Kuramochi, Hironaga Satake, Yoshiaki Shindo, Akira Doi, Jyunichiro Nasu, Haruhiro Yamashita and Yoshiyuki Yamaguchi

    Citation: BMC Cancer 2019 19:941

    Content type: Study protocol

    Published on:

  32. The clinical target volume (CTV) for postoperative radiotherapy for thoracic esophageal squamous cell carcinoma (TESCC) needs to be defined. The study aim was to map metastatic lymph nodes (LNMs) in a computed...

    Authors: Jing Yu, Wen Ouyang, Chunyang Li, Jiuling Shen, Yu Xu, Junhong Zhang and Conghua Xie

    Citation: BMC Cancer 2019 19:927

    Content type: Research article

    Published on:

  33. Fibrin-associated diffuse large B-cell lymphoma (FA-DLBCL) is a rare Epstein-Barr virus (EBV) positive lymphoproliferative disorder included in the current World Health Organization (WHO) classification. It ar...

    Authors: Magda Zanelli, Maurizio Zizzo, Marco Montanaro, Vito Gomes, Giovanni Martino, Loredana De Marco, Giulio Fraternali Orcioni, Maria Paola Martelli and Stefano Ascani

    Citation: BMC Cancer 2019 19:916

    Content type: Case report

    Published on:

  34. Oncoplastic surgery techniques lead to a rearrangement of the breast tissue and impede target definition during adjuvant radiotherapy (RT). The aim of this study was to assess local control rates after immedia...

    Authors: Kai Joachim Borm, Christine Schönknecht, Andrea Nestler, Markus Oechsner, Birgit Waschulzik, Stephanie Elisabeth Combs, Stefan Münch, Markus Niemeyer and Marciana Nona Duma

    Citation: BMC Cancer 2019 19:907

    Content type: Research article

    Published on:

  35. Following definitive chemoradiation for anal squamous cell carcinoma (ASCC), patients face a variety of chronic issues including: bowel dysfunction, accelerated bone loss, sexual dysfunction, and psychosocial ...

    Authors: Marissa B. Savoie, Angela Laffan, Cristina Brickman, Bevin Daniels, Anna Levin, Tami Rowen, James Smith, Erin L. Van Blarigan, Thomas A. Hope, J. Michael Berry-Lawhorn, Mekhail Anwar and Katherine Van Loon

    Citation: BMC Cancer 2019 19:906

    Content type: Review

    Published on:

  36. Prostate cancer (PCa) is the second most common cancer among men. New imaging-modalities have increased the diagnosed patients with limited number of metastasis after primary curative therapy, introducing so-c...

    Authors: Giulia Marvaso, Delia Ciardo, Giulia Corrao, Sara Gandini, Cristiana Fodor, Dario Zerini, Damaris Patricia Rojas, Matteo Augugliaro, Giuseppina Bonizzi, Salvatore Pece, Federica Cattani, Ketti Mazzocco, Francesco Alessandro Mistretta, Gennaro Musi, Sarah Alessi, Giuseppe Petralia…

    Citation: BMC Cancer 2019 19:903

    Content type: Study protocol

    Published on:

  37. The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory a...

    Authors: Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, Christian Oehlschlegel, Olivia Pagani, Bernhard Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman and Thomas Ruhstaller

    Citation: BMC Cancer 2019 19:902

    Content type: Research article

    Published on:

  38. Poly (ADP-ribose) Polymerase (PARP) inhibitors are promising novel radiosensitisers. Pre-clinical models have demonstrated potent and tumour-specific radiosensitisation by PARP inhibitors. Olaparib is a PARP i...

    Authors: R. de Haan, E. van Werkhoven, M.M. van den Heuvel, H. M. U. Peulen, G. S. Sonke, P. Elkhuizen, M. W. M. van den Brekel, M. E. T. Tesselaar, C. Vens, J. H. M. Schellens, B. van Triest and M. Verheij

    Citation: BMC Cancer 2019 19:901

    Content type: Study protocol

    Published on:

  39. This study aimed to evaluate the efficacy, side-effects and resistance mechanisms of first-line afatinib in a real-world setting.

    Authors: Gwo-Fuang Ho, Chee-Shee Chai, Adlinda Alip, Mohd Ibrahim A. Wahid, Matin Mellor Abdullah, Yoke-Ching Foo, Soon-Hin How, Adel Zaatar, Kai-Seng Lam, Kin-Wah Leong, John-Seng-Hooi Low, Mastura Md Yusof, Erica Chai-Yong Lee, Yok-Yong Toh and Chong-Kin Liam

    Citation: BMC Cancer 2019 19:896

    Content type: Research article

    Published on:

  40. Bone metastases represent an important source of morbidity in cancer patients, mostly due to severe pain. Radiotherapy is an established symptomatic treatment for painful bone metastases, however, when convent...

    Authors: Carole Mercier, Piet Dirix, Piet Ost, Charlotte Billiet, Ines Joye, Peter Vermeulen, Yolande Lievens and Dirk Verellen

    Citation: BMC Cancer 2019 19:876

    Content type: Study protocol

    Published on:

  41. This study investigated a large number of patients to develop a predictive nomogram for survival and a web-based survival rate calculator that can dynamically predict the long-term survival of patients with pr...

    Authors: Ju-Li Lin, Jian-Xian Lin, Ping Li, Jian-Wei Xie, Jia-bin Wang, Jun Lu, Qi-Yue Chen, Long-long Cao, Chang-Ming Huang and Chao-Hui Zheng

    Citation: BMC Cancer 2019 19:873

    Content type: Research article

    Published on:

  42. Pseudomyogenic hemangioendothelioma (PMHE) is a rare endothelial neoplasm that involves the bones in only 14% of all cases. The optimal treatment strategy has not been established. We herein report a case of p...

    Authors: Shinya Otani, Robert Nakayama, Tetsuya Sekita, Toru Hirozane, Naofumi Asano, Kazumasa Nishimoto, Aya Sasaki, Hajime Okita, Hideo Morioka, Masaya Nakamura and Morio Matsumoto

    Citation: BMC Cancer 2019 19:872

    Content type: Case report

    Published on:

  43. Metformin is proven to improve the prognosis of various cancers, but it is unknown if metformin could ameliorate hypopharyngeal cancer in diabetes mellitus patients. This was a retrospective cohort study, and ...

    Authors: Yung-An Tsou, Wen-Dien Chang, Jian-Ji Lu, Tsu-Fang Wu, Hsiao-Ling Chen, Chuan-Mu Chen and Ming Hsui Tsai

    Citation: BMC Cancer 2019 19:862

    Content type: Research article

    Published on:

  45. Selecting the appropriate patients to receive immunotherapy (IO) remains a challenge due to the lack of optimal biomarkers. The presence of liver metastases has been implicated as a poor prognostic factor in p...

    Authors: Mehmet Asim Bilen, Julie M. Shabto, Dylan J. Martini, Yuan Liu, Colleen Lewis, Hannah Collins, Mehmet Akce, Haydn Kissick, Bradley C. Carthon, Walid L. Shaib, Olatunji B. Alese, Conor E. Steuer, Christina Wu, David H. Lawson, Ragini Kudchadkar, Viraj A. Master…

    Citation: BMC Cancer 2019 19:857

    Content type: Research article

    Published on:

  46. Despite recent advances in the treatment of multiple myeloma, the disease constantly relapses and is still considered as incurable. The current knowledge about the biological mechanisms underlying resistance t...

    Authors: Lina Benaniba, Benoit Tessoulin, Sabrina Trudel, Catherine Pellat-Deceunynck, Martine Amiot, Stéphane Minvielle, Pierre Antoine Gourraud, Sophie de Visme, Hervé Maisonneuve, Anne Lok, Steven Le Gouill, Philippe Moreau and Cyrille Touzeau

    Citation: BMC Cancer 2019 19:855

    Content type: Study protocol

    Published on:

  47. Recent years have witnessed the rapid evolution of therapies in chronic-phase chronic myeloid leukemia (CP-CML). To assess the efficacy and tolerability of all reported front-line treatments for patients with ...

    Authors: Lu Tang, Huan Zhang, Yi-zhong Peng, Cheng-gong Li, Hui-wen Jiang, Min Xu, Heng Mei and Yu Hu

    Citation: BMC Cancer 2019 19:849

    Content type: Research article

    Published on:

  48. To explore the association between biologically effective dose (BED) and survival rates in Child-Pugh A classification (CP-A) small hepatocellular carcinoma (HCC) patients treated with stereotactic body radiat...

    Authors: Jing Sun, Tao Zhang, Jia Wang, Wengang Li, Aimin Zhang, Weiping He, Dan Zhang, Dong Li, Junqiang Ding and Xuezhang Duan

    Citation: BMC Cancer 2019 19:846

    Content type: Research article

    Published on:

  49. Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellen...

    Authors: David A. Palma, Robert Olson, Stephen Harrow, Rohann J. M. Correa, Famke Schneiders, Cornelis J. A. Haasbeek, George B. Rodrigues, Michael Lock, Brian P. Yaremko, Glenn S. Bauman, Belal Ahmad, Devin Schellenberg, Mitchell Liu, Stewart Gaede, Joanna Laba, Liam Mulroy…

    Citation: BMC Cancer 2019 19:816

    Content type: Study protocol

    Published on:

  50. Plasma cell disorders are a rare group of hematological malignancies that accounts for 10% of all hematological neoplasms. Solitary plasmacytomas are rarer entities accounting for less than 5% of all the plasm...

    Authors: Sridevi Hanaganahalli Basavaiah, Flora D. Lobo, Cheryl Sarah Philipose, Pooja K. Suresh, Saraswathy Sreeram, Hema Kini, Kausalya K. Sahu and Krishna Prasad

    Citation: BMC Cancer 2019 19:801

    Content type: Research article

    Published on:

Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us